HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on aTyr Pharma (NASDAQ:LIFE) and maintains a $35 price target.
May 23, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on aTyr Pharma and maintains a $35 price target.
The Buy rating and maintained $35 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for aTyr Pharma's stock in the short term. This reaffirmation of the Buy rating can potentially boost investor confidence and lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100